In This Section

Program

Please note that this meeting will take place as an in-person event in Philadelphia and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Wednesday, June 24

Thursday, June 25

Friday, June 26

Saturday, June 27

Wednesday, June 24

REGISTRATION

1-8 p.m. | Grand Ballroom Foyer

WELCOME AND OPENING Keynote

5-6 p.m. | Grand Ballroom ABC

  • 5 p.m. | Welcome and Introduction of Keynote Speaker
    Michael Green, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 5:10 p.m. | Opening Keynote Lecture
    Ron Levy, Stanford University, Stanford, California

Plenary Session 1: Antibodies through the eras

6-7:50 p.m. | Grand Ballroom ABC

Session Chair: Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 6 p.m. | Dave Maloney, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • 6:30 p.m. | Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, New York
  • 7 p.m. | Bispecific antibodies in B-cell lymphomas: Redefining immune engagement in the therapeutic landscape
    Elicia Penuel, Genentech/Roche, San Francisco, California
  • 7:30 p.m. | Panel Discussion/Q&A

Reception

7:50-9:30 p.m.

Thursday, June 25

Registration

7 a.m. – 7 p.m. | Grand Ballroom Foyer

Breakfast

7-8 a.m.

Workshop: AI in lymphoma: foundation models and beyond

7:15-7:45 a.m. | Grand Ballroom ABC 

  • Jansen Seheult, Mayo Clinic, Rochester, Minnesota, Minneapolis 

Plenary Session 2: Next Generation Clinical Assessment

8-9:50 a.m. | Grand Ballroom ABC          

Session Chair: David Scott, University of British Columbia, Vancouver, British Columbia, Canada

  • 8 a.m. | Davide Rossi, Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland
  • 8:30 a.m. | Genetics to inform therapy in lymphoma
    Margaret Shipp, Dana Farber Cancer Institute, Boston, Massachusetts
  • 9 a.m. | Integrating the microenvironment and omics into clinical workflows
    Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 9:30 a.m. | Panel Discussion/Q&A

Coffee Break

9:50-10:10 a.m. | Grand Ballroom Foyer

Plenary Session 3: The Lymphoma Microenvironment

10:10 a.m.-12 p.m. | Grand Ballroom ABC

Session Chair: Christian Steidl, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

  • 10:10 a.m. | Spatial and immunological features of high-risk DLBCL
    Anand D Jeyasekharan, Cancer Science Institute of Singapore, National University of Singapore, Singapore
  • 10:40 a.m. | Using the microenvironment to predict response to therapy
    Justin Kline, University of Chicago, Chicago, Illinois
  • 11:10 a.m. | Hodgkin lymphoma tumor microenvironment
    Christian Steidl, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
  • 11:40 | Panel Discussion/Q&A

Lunch on own

12-2 p.m.

Plenary Session 4: Spatial Analysis of Lymphoma

2-3:50 p.m. | Grand Ballroom ABC

Session Chair: Erin Parry, Dana Farber Cancer Institute, Boston, Massachusetts

  • 2 p.m. | Dark zone lymphomas
    David Scott, University of British Columbia, Vancouver, British Columbia, Canada
  • 2:30 p.m. | Transformation
    Erin Parry, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 3 p.m. | Decoding lymphoma morphology with computer vision: A foundational approach
      Jansen Seheult, Mayo Clinic, Rochester, Minnesota, Minneapolis
  • 3:30 p.m. | Panel Discussion/Q&A

Break

3:50-4:10 p.m.

Spotlight on Proffered Abstracts

4:10-5:10 p.m. | Grand Ballroom ABC

Session Chair: Michael Green, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 4:10 p.m. | Cytokine-linked stromal remodeling in transformed follicular lymphoma impacts macrophage function and can be detected non-invasively
    Laura Beckmann, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4:16 p.m. | Bcl6-driven Cd70 -deficient Diffuse Large B-cell Lymphomas originate from innate-like cells with blunted CD4+ cytotoxic T-cell immune surveillance
    Elisa Mandato, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4:21 p.m. | BTG1 mutation induces an age-associated B cell precursor population with extranodal and brain-infiltrating potential in diffuse large B cell lymphoma via interleukin-21 hypersensitivity
    Yulai Zhou, Yale University, New Haven, Connecticut
  • 4:27 p.m. | BTK A428D is a recurrent pan-resistance mutation to BTK degraders in clinical trials
    Quinlan Sievers, Memorial Sloan Kettering Cancer Center, New York, New York
  • 4:34 p.m. | Mutant FOXO1 licenses MYC transformation of human germinal center B cells into dark-zone MYC-BCL2 high-grade B cell lymphomas
    Sabrina Giampaolo, The AIRC Institute of Molecular Oncology, Milano, Italy
  • 4:41 p.m. | Mechanisms and impact of bystander killing by CAR T cells
    Joanna Chorazeczewski, University of Chicago, Chicago, Illinois
  • 4:47 p.m. | Spatially resolved microenvironment profiling reveals distinct follicular lymphoma archetypes
    Abe Yoshiaki, MD Anderson Cancer Center, Houston, Texas
  • 4:53 p.m. | PKCδ-mediated feedback control of B-cell receptor signaling and its subversion in diffuse large B-cell lymphoma
    Ruifeng Sun, Yale University, New Haven, Connecticut

Poster Session

5:30-7:30 p.m. | Grand Ballroom D

Friday, June 26

Registration

7 a.m. – 6:30 p.m. | Grand Ballroom Foyer

Breakfast

7-8 a.m.

Workshop: ctDNA analyses of lymphoid malignancies

7:15-7:45 a.m. | Grand Ballroom ABC

  • Mark Roshchewski, Memorial Sloan Kettering Cancer, New York, New York

Plenary Session 5: New Targeted Therapeutic Strategies in Lymphoma

8-9:50 a.m. | Grand Ballroom ABC

Session Chair: Jason Westin, MD Anderson Cancer Center, Houston, Texas

  • 8 a.m. | Targeting BTK in CLL and other B-cell malignancies: Continuous progress with a continuous therapy
    Kerry Rogers, Ohio State University, Columbus, Ohio 
  • 8:30 a.m. | Multitargeted combination strategies to cure patients with large B-cell lymphoma
    Mark Roschewski, Memorial Sloan Kettering Cancer Center, New York, New York
  • 9 a.m. | Integrating novel agents into rational combinations
    Jason Westin
  • 9:30 a.m. | Panel Discussion/Q&A

break

9:50-10:10 a.m.

Plenary Session 6: Degraders in Lymphoma

10:10 a.m.-12 p.m. | Grand Ballroom ABC

Session Chair: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Ticino, Switzerland

  • 10:10 a.m. | Exploiting the E3 ligase FBXO21 as a novel therapeutic target and degrader in lymphoma
    Shannon Buckley, University of Utah, Salt Lake City, Utah
  • 10:40 a.m. | Resistance to BTK degraders
    Francesco Bertoni
  • 11:10 a.m. | Justin Taylor, University of Miami Miller School of Medicine, Miami, Florida
  • 11:40 p.m. | Panel Discussion/Q&A

Lunch on Own

12-2 p.m.

Plenary Session 7: Rare Lymphomas

2-3:50 p.m. | Grand Ballroom ABC

Session Chair: Jean Koff, Winship Cancer Institute of Emory University, Atlanta, Georgia

  • 2 p.m. | TP53-independent risk stratification in mantle cell lymphoma using a novel gene expression signature
    Jean Koff, Winship Cancer Institute of Emory University, Atlanta, Georgia
  • 2:30 p.m. | Navigating the landscape of peripheral T-cell lymphomas
    Teresa Palomero, Columbia University, New York, New York
  • 3 p.m. | Updates on the treatment of primary CNS lymphoma
    Christian Grommes, Memorial Sloan Kettering Cancer Center, New York, New York
  • 3:30 p.m. | Panel Discussion/Q&A

coffee break

3:50-4:10 p.m. | Grand Ballroom Foyer

Plenary Session 8: Advances in Cell Therapy

4:10-6 p.m. | Grand Ballroom ABC

Session Chair:  Marcela Maus, Massachusetts General Hospital, Boston, Massachusetts 

  • 4:10 p.m. | Novel CAR-T cells in lymphoma
    Marcela Maus
  • 4:40 p.m. | Armored CAR T cells
    Sarwish Rafiq, Winship Cancer Institute of Emory University, Atlanta, Georgia
  • 5:10 p.m. | Analysis of site-specific CAR T cell efficacy in LBCL and development of novel engineering strategies
    Laura Evgin, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
  • 5:40 p.m. | Panel Discussion/Q&A

break

6-6:20 p.m.

CAR T-Cell Emerging Toxicities

Organized in collaboration with the Hematologic Malignancies Working Group

6:20-7:30 p.m. | Grand Ballroom ABC

Moderator: Jean Koff, Winship Cancer Institute of Emory University, Atlanta, Georgia

  • 6:30 p.m. | Introduction and T-cell lymphomas after CAR-T
    Premal Lulla, Baylor College of Medicine, Houston, Texas
  • 6:40 p.m. | Panel Discussion=
    Premal Lulla, Baylor College of Medicine, Houston, Texas, United States
    Marcela Maus, Massachusetts General Hospital, Boston, Massachusetts
    Daniel Landsburg, University of Pennsylvania, Philadelphia, Pennsylvania
Saturday, June 27

Registration

7 a.m. – 1 p.m. | Grand Ballroom Foyer

Breakfast

7-8 a.m.

Workshop: Leveraging Spatial Technologies in Lymphoma

7:15-7:45 a.m. | Grand Ballroom ABC

  • Anand Jeyasekharan, National University of Singapore, Singapore, Singapore

Closing Keynote Lecture

8-9 a.m. | Grand Ballroom ABC

  • 8 a.m. | Introduction of Keynote Speaker
    Laura Pasqualucci, Columbia University Irving Comprehensive Cancer  Center, New York, New York
  • 8:10 a.m. | Michel Nussenzweig, Rockefeller University, New York, New York

Plenary Session 9: The Origins of Lymphoma

9-10:50 a.m. | Grand Ballroom ABC

Sessin Chair: Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, New York

  • 9 a.m. | Cells of origin for lymphoma
    Dinis Pedro Parente Calado, Francis Crick Institute, London, England, United Kingdom
  • 9:30 a.m. | Mouse models of mantle cell lymphoma
    Ron Jachimowicz, University Hospital Cologne, Germany
  • 10 a.m. | Laura Pasqualucci, Columbia University, New York, New York
  • 10:30 a.m. | Panel Discussion / Q&A

coffee break

10:50-11:10 a.m. | Grand Ballroom Foyer

Plenary Session 10: Epigenetics

11:10-12:30 p.m. | Grand Ballroom AB

Session Chair: Michael Green, The University of Texas MD Anderson Cancer Center,Houston, Texas

  • 11:10 a.m. | Targeting the BCL6 transcription factor in lymphoma
    Michael Green
  • 11:40 a.m. | Epigenetic regulation of the lymphoma microenvironment: from single-cell behavioral reprogramming to systems-level niche corruption
    Wendy Beguelin, New York University, New York, New York
  • 12:40 p.m. | Panel Discussion / Q&A

Closing Remarks

12:30 p.m.